New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
06:23 EDTAKRXAkorn guidance 'not a cause for alarm,' says Piper Jaffray
Piper Jaffray believes Akorn's 2014 guidance is "not a cause for alarm" given the depth of the company's pipeline. Piper says Akorn's long-term growth story remains intact and it keeps an Overweight rating on the stock despite lowering its price target for shares to $28 from $29.
News For AKRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
09:58 EDTAKRXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: 500.com (WBAI) downgraded to Hold from Buy at Deutsche Bank... Akorn (AKRX) downgraded to Hold after share rally at Needham... Allscripts (MDRX) downgraded to Market Perform from Outperform at Leerink... Bank of America (BAC) downgraded to Neutral from Buy at UBS... Bill Barrett (BBG) downgraded to Hold from Buy at KLR Group... CA Technologies (CA) downgraded to Underperform from Neutral at Credit Suisse... CBOE Holdings (CBOE) downgraded at BofA/Merrill... CONE Midstream (CNNX) downgraded to Sector Perform from Outperform at RBC Capital... Calamos (CLMS) downgraded to Underperform from Neutral at Credit Suisse... Crane (CR) downgraded to Market Perform from Outperform at FBR Capital... Dick's Sporting (DKS) downgraded to Equal Weight from Overweight at Barclays... EnerNOC (ENOC) downgraded to Buy from Strong Buy at Needham... Hercules Offshore (HERO) downgraded to Sell from Buy at Deutsche Bank... Insulet (PODD) downgraded at Oppenheimer... Intelsat (I) downgraded to Underperform from Neutral at Credit Suisse... Laredo Petroleum (LPI) downgraded to Market Perform from Outperform at Northland... Mavenir Systems (MVNR) downgraded to Equal Weight from Overweight at Morgan Stanley... Memorial Production (MEMP) downgraded to Underperform from Perform at Oppenheimer... Mobileye (MBLY) downgraded to Neutral from Buy at Dougherty... NTELOS (NTLS) downgraded to Market Perform from Outperform at Wells Fargo... Ocwen (OCN) downgraded to Sell from Neutral at Compass Point... Pegasystems (PEGA) downgraded to Neutral from Buy at Merriman... Performant Financial (PFMT) downgraded to Neutral from Buy at Compass Point... Pharmacyclics (PCYC) downgraded to Neutral from Buy at Goldman... Potbelly (PBPB) downgraded to Underweight from Overweight at Piper Jaffray... SYNNEX (SNX) downgraded to Hold from Buy at Stifel... Safe Bulkers (SB) downgraded at Credit Suisse... Sarepta (SRPT) downgraded to Market Perform from Outperform at Cowen... Seadrill Partners (SDLP) downgraded to Sector Perform from Outperform at RBC Capital... Spirit Realty (SRC) downgraded at RBC Capital... Transocean (RIG) downgraded to Sector Perform from Outperform at Iberia... UIL Holdings (UIL) downgraded to Neutral from Outperform at RW Baird... WCI Communities (WCIC) downgraded to Neutral from Buy at Citigroup... Walter Investment (WAC) downgraded to Neutral from Outperform at Credit Suisse.
07:24 EDTAKRXAkorn downgraded to Hold after share rally at Needham
Subscribe for More Information
06:49 EDTAKRXAkorn downgraded to Hold from Buy at Needham
Subscribe for More Information
06:39 EDTAKRXAkorn price target raised to $66 from $55 at Piper Jaffray
Subscribe for More Information
06:13 EDTAKRXAkorn price target raised to $65 from $43 at WallachBeth
Subscribe for More Information
February 26, 2015
13:05 EDTAKRXAkorn price target raised to $60 from $50 at Guggenheim
Guggenheim raised Buy rated Akron's price target to $60 from $50 following the Q4 report. The analyst believes Akorn is well positioned for upward earnings revisions that will drive shares higher in 2015.
07:17 EDTAKRXAkorn sees Q1 revenue down sequentially from Q4
Q1 revenue consensus $217.62M. The company said: "Based on several previously disclosed factors contributing to Q4 performance including higher-than-normal in-transit revenue at the end of the Q3, seasonality in the Hi-Tech Pharmacal cough and cold business and the successful resolution of backorders from the third quarter encountered due to clobetasol market dynamics, the company believes 1Q15 revenue will be below 4Q14 revenue. Akorn projects that consolidated net revenue will increase sequentially throughout 2015 due to a combination of seasonality in the business and the cumulative impact of new launches on quarterly revenue throughout the year."
07:14 EDTAKRXAkorn sees FY15 adjusted EPS $1.88-$1.98, consensus $1.82
Subscribe for More Information
07:12 EDTAKRXAkorn reports Q4 adjusted EPS 50c, consensus 45c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use